Stay updated with breaking news from Acute Rejection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AUSTIN, Texas, April 11, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.
World Organ Donation Day 2023: It is very important to understand the phenomenon of transplant rejection and the effects of Immunosuppressive drugs, read on to know all about both
Published: Apr 05, 2021 SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021. As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Ca...